# US 2024/0299347 A1 · Methods and compositions to treat huntington's disease by targeting alox5- mediated ferroptosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0299347 A1
- Document ID: US20240299347A1
- Status: Published application
- Kind: A1
- Application number: 18/601,908
- Filed: 2024-03-11
- Published: 2024-09-12
- Earliest claimed: 2023-03-10
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University in the City of New York
- Inventors: Wei GU
- Web page: https://patentgrep.com/patent/US20240299347A1

## CPC

- A61K 31/381: having five-membered rings
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4245: Oxadiazoles
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 113/11034: Arachidonate 5-lipoxygenase (1.13.11.34)
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C12N 2310/14: interfering nucleic acids [NA]
- G01N 2333/90241: acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are compositions and methods for treating or preventing Huntington's disease. In one aspect, the disclosed methods relate to targeting arachidonate 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (FLAP). The compositions and methods disclosed herein can be used as disease modifying therapies to enable treatment of Huntington's disease and related disorders earlier in disease progression and improve clinical outcomes.

## Claims

### Claim 1

A method of treating or preventing Huntington's disease in a subject in need thereof, comprising administering to said subject a composition that targets an acyl-CoA synthetase long-chain family member 4 (ACSL4)-independent ferroptosis pathway.

### Claim 2

A method of treating or preventing Huntington's disease in a subject in need thereof, comprising:
(i) identifying the subject as expressing mutant huntingtin (mHTT), and
(ii) administering to said subject a composition that targets an acyl-CoA synthetase long-chain family member 4 (ACSLA)-independent ferroptosis pathway.

### Claim 3

A method of treating or preventing Huntington's disease in a subject in need thereof, comprising:
(i) identifying the subject as having an increased expression level of arachidonate 5-lipoxygenase (ALOX5), and
(ii) administering to said subject a composition that targets an acyl-CoA synthetase long-chain family member 4 (ACSL4)-independent ferroptosis pathway.

### Claim 4

A method of treating or preventing Huntington's disease in a subject in need thereof, comprising:
(i) identifying the subject as having an increased expression level of 5-lipoxygenase-activating protein (FLAP), and
(ii) administering to said subject a composition that targets an acyl-CoA synthetase long-chain family member 4 (ACSLA)-independent ferroptosis pathway.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject expresses mHTT, an increased level of ALOX5, an increased level of FLAP, or a combination thereof.

### Claim 6 (depends on 2)

The methods of claim 2 wherein expression of mHTT is determined from a sample from the subject.

### Claim 7 (depends on 3, 4)

The method of claims 3-4, wherein expression level is determined from a sample from the subject.

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, wherein expression or expression level is a protein level, a mRNA expression level, or combination thereof.

### Claim 9 (depends on 2)

The method of claim 2, wherein the subject further expresses an increased level of ALOX5, an increased level of FLAP, or a combination thereof.

### Claim 10 (depends on 3)

The method of claim 3, wherein the subject further expresses mHTT, an increased level of FLAP, or a combination thereof.

### Claim 11 (depends on 4)

The method of claim 4, wherein the subject further expresses mHTT, an increased level of ALOX5, or a combination thereof.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the composition reduces ALOX5 expression in the subject compared to ALOX5 expression in a subject suffering from Huntington's disease or compared to ALOX5 expression in the subject before administration of the composition.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the composition reduces FLAP expression in the subject compared to FLAP expression in a subject suffering from Huntington's disease or compared to FLAP expression in the subject before administration of the composition.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the composition inhibits or reduces ALOX5 expression in the subject.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the composition inhibits or reduces FLAP expression in the subject.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises Zileuton.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises MK.886.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises docebenone (AA 861).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises boswellic acids.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises atreleuton (ABT-761 or VIA-2291).

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises setileuton (1,3,4-oxadiazole MK-0633

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises PF-4191834 or CJ-13610.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises Flavocoxid.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises an ALOX5 small interfering ribonucleic acid (siALOX5).

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises a FLAP small interfering ribonucleic acid (siFLAP).

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of claims 1-15, wherein the composition comprises an ALOX5 short-hairpin ribonucleic acid (shALOX5).

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of claims 1-15, wherein the composition comprises a FLAP short-hairpin ribonucleic acid (shFLAP).

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises a guide RNA or a single-molecule guide RNA comprising a spacer sequence that is complementary to a portion of a nucleic acid sequence encoding ALOX5.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the composition comprises a guide RNA or a single-molecule guide RNA comprising a spacer sequence that is complementary to a portion of a nucleic acid sequence encoding FLAP.

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, wherein the guide RNA or the single molecule guide RNA is pre-complexed with a DNA endonuclease.

### Claim 31 (depends on 30)

The method of claim 30, wherein the DNA endonuclease is a Cas9 or dCas9 endonuclease.

### Claim 32 (depends on 24, 25, 26, 27, 28, 29)

The method of any one of claims 24-29, wherein the composition comprises a vector.

### Claim 33 (depends on 26, 27, 28, 29)

The method of any one of claims 26-29, wherein the composition comprises a viral vector, wherein the viral vector encapsulates a nucleic acid encoding the shALOX5, a nucleic acid encoding the shFLAP, a nucleic acid encoding the guide ribonucleic acid or a single molecule guide RNA comprising a spacer sequence that is complementary to a portion of a nucleic acid sequence encoding ALOX5, or a nucleic acid encoding the guide ribonucleic acid or a single molecule guide RNA comprising a spacer sequence that is complementary to a portion of a nucleic acid sequence encoding FLAP.

### Claim 34 (depends on 33)

The method of claim 33, wherein the viral vector is an adeno-associated vector (AAV).

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the subject is a mammal.

### Claim 36 (depends on 35)

The method of claim 35, wherein the mammal is a human.

### Claim 37 (depends on 36)

The method of claim 36, wherein the human subject has an increased expression level of ALOX5 compared to a human subject not suffering from Huntington's disease.

### Claim 38 (depends on 36)

The method of claim 36, wherein the human subject has an increased expression level of FLAP compared to a human subject not suffering from Huntington's disease.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of claims 1-38, wherein the composition is delivered systemically.

### Claim 40

A composition for treating or preventing Huntington's disease, comprising a composition targeting the ACSLA-independent ferroptosis pathway.

### Claim 41 (depends on 40)

The composition of claim 40, wherein the composition reduces arachidonate 5-lipoxygenase (ALOX5) expression in a subject in need thereof.

### Claim 42 (depends on 40, 41)

The composition of claim 40 or 41, wherein the composition reduces 5-lipoxygenase-activating protein (FLAP) expression in a subject in need thereof.

### Claim 43 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises Zileuton.

### Claim 44 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises MK.886.

### Claim 45 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises docebenone (AA 861).

### Claim 46 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises boswellic acids.

### Claim 47 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises atreleuton (ABT-761 or VIA-2291).

### Claim 48 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises setileuton (1,3,4-oxadiazole MK-0633).

### Claim 49 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises PF-4191834 or CJ-13610.

### Claim 50 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises flavocoxid.

### Claim 51 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises an ALOX5 small interfering ribonucleic acid (siALOX5).

### Claim 52 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises a FLAP small interfering ribonucleic acid (siFLAP).

### Claim 53 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises an ALOX5 short-hairpin ribonucleic acid (shALOX5).

### Claim 54 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises a FLAP short-hairpin ribonucleic acid (shFLAP).

### Claim 55 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises a guide ribonucleic acid or a single molecule guide RNA comprising a spacer sequence that is complementary to a portion of a nucleic acid sequence encoding ALOX5.

### Claim 56 (depends on 40, 41, 42)

The composition of any one of claims 40-42, wherein the composition comprises a guide ribonucleic acid or a single molecule guide RNA comprising a spacer sequence that is complementary to a portion of a nucleic acid sequence encoding FLAP.

### Claim 57 (depends on 55, 56)

The composition of any one of claim 55 or 56, wherein the guide RNA or the single molecule guide RNA is pre-complexed with a DNA endonuclease.

### Claim 58 (depends on 57)

The composition of claim 57, wherein the DNA endonuclease is a Cas9 or dCas9 endonuclease.

### Claim 59 (depends on 53, 54, 55, 56, 57, 58)

The composition of any one of claims 53-58, wherein the composition further comprises a viral vector, wherein the viral vector encapsulates a nucleic acid encoding the shALOX5, a nucleic acid encoding the shFLAP, a nucleic acid encoding the guide ribonucleic acid or a single molecule guide RNA comprising a spacer sequence that is complementary to a portion of a nucleic acid sequence encoding ALOX5, or a nucleic acid encoding the guide ribonucleic acid or a single molecule guide RNA comprising a spacer sequence that is complementary to a portion of a nucleic acid sequence encoding FLAP.

### Claim 60 (depends on 59)

The composition of claim 59, wherein the viral vector is an AAV vector.

### Claim 61

A small interfering ribonucleic acid (siRNA) targeting the acyl-CoA synthetase long-chain family member 4 (ACSL4)-independent ferroptosis pathway.

### Claim 62 (depends on 61)

The siRNA of claim 61, wherein the siRNA comprises an ALOX5 small interfering ribonucleic acid (siALOX5).

### Claim 63 (depends on 61)

The siRNA of claim 61, wherein the siRNA comprises a FLAP small interfering ribonucleic acid (siFLAP).

### Claim 64 (depends on 61, 62, 63)

A vector comprising the siRNA of any one of claims 61-63.

### Claim 65

A nucleic acid comprising a sequence encoding a short hairpin ribonucleic acid (shRNA) targeting the acyl-CoA synthetase long-chain family member 4 (ACSLA)-independent ferroptosis pathway.

### Claim 66 (depends on 65)

The nucleic acid of claim 65, wherein the shRNA is an ALOX5 short-hairpin ribonucleic acid (shALOX5).

### Claim 67 (depends on 65)

The nucleic acid of claim 65, wherein the shRNA is a FLAP short-hairpin ribonucleic acid (shFLAP).

### Claim 68 (depends on 65, 66, 67)

A vector comprising the nucleic acid of any one of claims 65-67.

### Claim 69 (depends on 65, 66, 67)

A viral vector comprising the nucleic acid of any one of claims 65-67.

### Claim 70 (depends on 69)

The viral vector of claim 69, wherein the viral vector is an AAV vector.

### Claim 71

A method of diagnosing Huntington's disease in a subject comprising:
(i) determining the level of arachidonate 5-lipoxygenase (ALOX5) in the subject; and
(ii) diagnosing the subject with Huntington's disease if the level of ALOX5 expression in the subject is increased as compared to a subject not suffering from Huntington's disease.

### Claim 72

A method of diagnosing Huntington's disease in a subject comprising:
(i) determining the level of 5-lipoxygenase-activating protein (FLAP) in the subject; and
(ii) diagnosing the subject with Huntington's disease if the level of FLAP expression in the subject is increased as compared to a subject not suffering from Huntington's disease.
